Our findings suggest a generally higher expression of PD-1 and PD-L1 in cHL patients with pre-existing rheumatic diseases, possibly induced by a higher inflammatory activity in patients with rheumatic diseases. The gene discussed is PDCD1; the disease is classic Hodgkin lymphoma.